PPARG and metabolic disease: Hence, as an FDA-approved clinical drug, CLQ may be a new non-TZD selective PPARγ agonist and further evidence should be provided to establish whether CLQ performs a similar function in the treatment of metabolic diseases, including insulin resistance and hyperglycemia.